UK – NICE recommends Revlimid for newly diagnosed multiple myeloma patients

Bristol Myers Squibb’s (BMS) Revlimid (lenalidomide) has received a recommendation from the UK’s National Institute of Health and Care Excellence (NICE) for newly diagnosed multiple myeloma patients.

In its Final Appraisal Document (FAD), NICE recommended Revlimid as a maintenance treatment after autologous stem cell transplant (ASCT) for newly diagnosed multiple myeloma in adults.

In September 2020, NICE initially turned down NHS funding of Revlimid in this indication, after concluding that the cost-effectiveness estimates for the drug in this setting were uncertain…